<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230314057713N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-10-23</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of cinnamon on knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of cinnamon extract on reducing pain and improving function in patients with knee osteoarthritis compared to diclofenac gel.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/86947</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be performed using the randomized permutation block method.
The block size is considered to be 4 and the ratio of drug to control in each group is equal to (1:1).The generation of random sequences will be performed by the methodologist.
To conceal the treatment process, random codes are written on the boxes, Blinding description: The cinnamon and diclofenac gel product will be prepared in a single form, with the same label and similar odor and color by adding color and essential oil by a pharmaceutical specialist in the Medicinal Plants Laboratory of the Faculty of Iranian Medicine, Babol. To ensure proper blinding and equalization of sensory conditions of the two groups (cinnamon gel and diclofenac gel), a very small percentage of cinnamon essential oil will be used in the can containing diclofenac gel.
This procedure is done to maintain the integrity of the blinding and prevent participants or assessors from identifying the intervention group. The only person who knows the nature of the drugs is the pharmacist who manufactured the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Topical gel containing cinnamon bark essential oil. First, the pure essential oil of this plant is procured from Giah Kala Company. Subsequently, the gel base is prepared using Carbomer 940 and distilled water: Carbomer 940 is gradually added to distilled water under continuous magnetic stirring until a preliminary gel structure forms. Next, cinnamon bark essential oil is slowly incorporated into the gel base and thoroughly mixed to ensure uniform dispersion throughout the gel. To enhance the solubility of the essential oil and improve skin permeability, varying concentrations of propylene glycol are added as a co-solvent and absorption enhancer, and completely blended into the formulation. Methylparaben and propylparaben are included as preservatives to prevent microbial growth and enhance formulation stability. In the final step, triethanolamine is added dropwise to the mixture to neutralize the acidic groups of Carbomer, thereby yielding a gel with appropriate viscosity and pH.  The final formulation is standardized based on the concentration of its active constituent, cinnamaldehyde. Quantification of cinnamaldehyde is performed using High-Performance Liquid Chromatography (HPLC), a method known for its high accuracy and precision in measuring this compound. Additionally, total phenolic content is determined using the Folin–Ciocalteu reagent. Furthermore, to ensure product safety, microbiological quality control tests—including total microbial count, absence of pathogenic microorganisms (such as *Pseudomonas aeruginosa*, *Escherichia coli*, and *Staphylococcus aureus*), and assessment for fungi and yeasts—are conducted in accordance with pharmacopoeial guidelines. One knuckle of the topical product every eight hours. Intervention 2: Control group: Control group: 60 grams of 1% diclofenac gel from Sobhan Pharmaceutical Company, one knuckle of the topical product every eight hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mozafar Ekhlasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Modares Blvd. Shahid Motahari St. Tarbiat St.</address>
        <city>Bourojen</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8871833988</zip>
        <telephone>+98 38 3422 4372</telephone>
        <email>mozafareghlasi@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Ali Mozaffarpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Babol University of Medical Sciences, Faculty of Traditional Iranian Medicine, Ganj Afroz Street</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 3219 4730</telephone>
        <email>Seyyedali1357@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 50 and 80 years
Osteophyte severity grade 1 to 3 according to the Kellgren-Allrens classification
Visual Analog Scale (VAS) score less than or equal to 4 to 8 in X.ray</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Participation in another clinical study in the past 6 months
Cognitive or mental disorder
Use of oral and intra-articular corticosteroids in the past two months
People with a history of allergies to herbal medicines
Skin disease at the joint site
Patients with acute arthritis, osteoarthritis secondary to rheumatological diseases such as rheumatoid arthritis and gout, infectious arthritis, metabolic arthritis, traumatic arthritis, uncontrolled diabetes, known heart, liver, cancer cases
Surgical joint replacement
Fibromyalgia, radiculopathy, and neuropathy
Those who are unable to tolerate the study and complete the treatment and follow-up period
Patients who take glucosamine, chondroitin sulfate, and muscle relaxants at the same time</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Topical gel containing cinnamon bark essential oil. First, the pure essential oil of this plant is procured from Giah Kala Company. Subsequently, the gel base is prepared using Carbomer 940 and distilled water: Carbomer 940 is gradually added to distilled water under continuous magnetic stirring until a preliminary gel structure forms. Next, cinnamon bark essential oil is slowly incorporated into the gel base and thoroughly mixed to ensure uniform dispersion throughout the gel. To enhance the solubility of the essential oil and improve skin permeability, varying concentrations of propylene glycol are added as a co-solvent and absorption enhancer, and completely blended into the formulation. Methylparaben and propylparaben are included as preservatives to prevent microbial growth and enhance formulation stability. In the final step, triethanolamine is added dropwise to the mixture to neutralize the acidic groups of Carbomer, thereby yielding a gel with appropriate viscosity and pH.  The final formulation is standardized based on the concentration of its active constituent, cinnamaldehyde. Quantification of cinnamaldehyde is performed using High-Performance Liquid Chromatography (HPLC), a method known for its high accuracy and precision in measuring this compound. Additionally, total phenolic content is determined using the Folin–Ciocalteu reagent. Furthermore, to ensure product safety, microbiological quality control tests—including total microbial count, absence of pathogenic microorganisms (such as *Pseudomonas aeruginosa*, *Escherichia coli*, and *Staphylococcus aureus*), and assessment for fungi and yeasts—are conducted in accordance with pharmacopoeial guidelines. One knuckle of the topical product every eight hours.</i_keyword>
      <i_keyword>Control group: Control group: 60 grams of 1% diclofenac gel from Sobhan Pharmaceutical Company, one knuckle of the topical product every eight hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score on the VAS questionnaire. Timepoint: Five self-assessment sessions: before the start of the intervention and on days 7, 14, 21, and 28 after the intervention. Method of measurement: VAS questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain score and symptom improvement, physical activity, and quality of life in patients with osteoarthritis from the Knee injury and Osteoarthritis Outcome Score (KOOS) tool. Timepoint: Three evaluations by a doctor: at the beginning of treatment, after 4 weeks of starting treatment, and 4 weeks after stopping treatment. Method of measurement: KOOS tool.</sec_outcome>
      <sec_outcome>Pain score from VAS tool. Timepoint: Three evaluations by a doctor: at the beginning of treatment, after 4 weeks of starting treatment, and 4 weeks after stopping treatment. Method of measurement: VAS tool.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-13</approval_date>
        <contact_name>Research Ethics Committees of Babol University of Medical Sciences</contact_name>
        <contact_address>Deputy of research and technology, University of Medical Sciences, Ganjafrooz Street, Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
